

Ben Tran

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6518292/publications.pdf>

Version: 2024-02-01

12
papers

1,382
citations

1307366

7
h-index

1281743

11
g-index

12
all docs

12
docs citations

12
times ranked

3279
citing authors

#	ARTICLE	IF	CITATIONS
1	Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. <i>Science Translational Medicine</i> , 2016, 8, 346ra92.	5.8	1,036
2	Cancer Genomics: Technology, Discovery, and Translation. <i>Journal of Clinical Oncology</i> , 2012, 30, 647-660.	0.8	173
3	Feasibility of real time next generation sequencing of cancer genes linked to drug response: Results from a clinical trial. <i>International Journal of Cancer</i> , 2013, 132, 1547-1555.	2.3	76
4	Expanding the role of small-molecule PSMA ligands beyond PET staging of prostate cancer. <i>Nature Reviews Urology</i> , 2020, 17, 107-118.	1.9	41
5	PSMA targeting in metastatic castration-resistant prostate cancer: where are we and where are we going?. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110538.	1.4	21
6	Relationship between Circulating Lipids and Cytokines in Metastatic Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2021, 13, 4964.	1.7	13
7	Chemotherapy and biologic use in the routine management of metastatic colorectal cancer in Australia: is clinical practice following the evidence?. <i>Internal Medicine Journal</i> , 2019, 49, 446-454.	0.5	12
8	Exploring the feasibility and utility of exome-scale tumour sequencing in a clinical setting. <i>Internal Medicine Journal</i> , 2018, 48, 786-794.	0.5	6
9	Molecular classification of hormone-sensitive and castration-resistant prostate cancer, using nonnegative matrix factorization molecular subtyping of primary and metastatic specimens. <i>Prostate</i> , 2022, 82, 993-1002.	1.2	2
10	Utilisation of systemic therapy options in routine treatment of metastatic colorectal cancer in Australia. <i>Internal Medicine Journal</i> , 2020, 50, 165-172.	0.5	1
11	Circulating tumour cells (CTCs) and PSMA PET correlates in the phase I PRINCE trial of ¹⁷⁷ Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC). <i>Journal of Clinical Oncology</i> , 2022, 40, 5027-5027.	0.8	1
12	Impact of the evolution in RAS mutation analysis in Australian patients with metastatic colorectal cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, , .	0.7	0